- Home
- CXAI vs BLRX Comparison
CXAI vs BLRX Comparison
Compare CXAI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- BLRX
- Stock Information
- Founded
- CXAI N/A
- BLRX 2003
- Country
- CXAI United States
- BLRX Israel
- Employees
- CXAI N/A
- BLRX N/A
- Industry
- CXAI EDP Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CXAI Technology
- BLRX Health Care
- Exchange
- CXAI Nasdaq
- BLRX Nasdaq
- Market Cap
- CXAI 16.0M
- BLRX 17.2M
- IPO Year
- CXAI N/A
- BLRX 2011
- Fundamental
- Price
- CXAI $0.72
- BLRX $3.76
- Analyst Decision
- CXAI
- BLRX Strong Buy
- Analyst Count
- CXAI 0
- BLRX 2
- Target Price
- CXAI N/A
- BLRX $19.00
- AVG Volume (30 Days)
- CXAI 630.4K
- BLRX 32.7K
- Earning Date
- CXAI 11-11-2025
- BLRX 08-14-2025
- Dividend Yield
- CXAI N/A
- BLRX N/A
- EPS Growth
- CXAI N/A
- BLRX N/A
- EPS
- CXAI N/A
- BLRX N/A
- Revenue
- CXAI $6,005,000.00
- BLRX $17,251,000.00
- Revenue This Year
- CXAI N/A
- BLRX N/A
- Revenue Next Year
- CXAI $60.00
- BLRX N/A
- P/E Ratio
- CXAI N/A
- BLRX N/A
- Revenue Growth
- CXAI N/A
- BLRX 1.19
- 52 Week Low
- CXAI $0.61
- BLRX $2.30
- 52 Week High
- CXAI $2.54
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- CXAI 41.98
- BLRX 47.80
- Support Level
- CXAI $0.70
- BLRX $3.68
- Resistance Level
- CXAI $0.79
- BLRX $4.11
- Average True Range (ATR)
- CXAI 0.05
- BLRX 0.26
- MACD
- CXAI 0.01
- BLRX 0.03
- Stochastic Oscillator
- CXAI 56.74
- BLRX 36.17
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.